Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Medical Genetic Department, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mol Cell Biochem. 2024 Apr;479(4):859-868. doi: 10.1007/s11010-023-04766-4. Epub 2023 May 24.
The role of inflammation has been proven in acute myocardial infarction (AMI) pathogenesis. Due to the effect of NLRP3 gene expression in the inflammation process of MI, we aimed to explore the expression changes and diagnostic power of four inflammation-related miRNAs including miR-17-3p, miR-101-3p, miR-335-3p, miR-296-3p and their potential target, NLRP3, in ST-segment elevation myocardial infarction (STEMI), and non-STEMI (NSTEMI) patients as two major classes of AMI. The expression level of these genes were evaluated in 300 participants equally divided into three groups of STEMI, NSTEMI, and control using quantitative real-time PCR. The expression level of NLRP3 was upregulated in STEMI and NSTEMI patients compared to control subjects. Besides, the expression levels of miR-17-3p, miR-101-3p, and miR-296-3p were significantly downregulated in STEMI and NSTEMI patients compared to controls. The increased expression of NLRP3 had a very strong inverse correlation with miR-17-3p in patients with STEMI and with miR-101-3p in the STEMI and NSTEMI patients. ROC curve analysis showed that the expression level of miR-17-3p had the highest diagnostic power for discrimination between STEMI patients and controls. Remarkably, the combination of all markers resulted in a higher AUC. In summary, there is a significant association between the expression levels of miR-17-3p, miR-101-3p, miR-335-3p, miR-296-3p, and NLRP3 and the incidence of AMI. Although the miR-17-3p expression level has the highest diagnostic power to distinguish between STEMI patients and control subjects, the combination of these miRNAs and NLRP3 could serve as a novel potential diagnostic biomarker of STEMI.
炎症在急性心肌梗死（AMI）发病机制中的作用已得到证实。由于 NLRP3 基因表达在 MI 炎症过程中的作用，我们旨在探索四个与炎症相关的 miRNA（miR-17-3p、miR-101-3p、miR-335-3p 和 miR-296-3p）及其潜在靶点 NLRP3 在 ST 段抬高型心肌梗死（STEMI）和非 ST 段抬高型心肌梗死（NSTEMI）患者中的表达变化和诊断能力，这两种 AMI 主要类型。使用定量实时 PCR 评估 300 名参与者中这些基因的表达水平，这些参与者平均分为 STEMI、NSTEMI 和对照组三组。与对照组相比，STEMI 和 NSTEMI 患者的 NLRP3 表达上调。此外，与对照组相比，STEMI 和 NSTEMI 患者的 miR-17-3p、miR-101-3p 和 miR-296-3p 的表达水平显著下调。STEMI 患者中 NLRP3 的表达增加与 miR-17-3p 呈很强的负相关，而在 STEMI 和 NSTEMI 患者中与 miR-101-3p 呈很强的负相关。ROC 曲线分析显示，miR-17-3p 的表达水平对区分 STEMI 患者和对照组具有最高的诊断能力。值得注意的是，所有标志物的组合导致 AUC 更高。总之，miR-17-3p、miR-101-3p、miR-335-3p、miR-296-3p 和 NLRP3 的表达水平与 AMI 的发生有显著相关性。虽然 miR-17-3p 的表达水平具有最高的诊断能力来区分 STEMI 患者和对照组，但这些 miRNA 和 NLRP3 的组合可以作为 STEMI 的新型潜在诊断生物标志物。
